List view / Grid view
29 July 2025 | By Eurofins Discovery
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
A new international framework introduces rigorous validity standards for the use of brain organoids and iPSC-derived models in studying neuropsychiatric disorders. These guidelines aim to accelerate drug discovery and bring precision treatments closer to reality.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
AI will not replace drug discovery, but it might finally fix one of its most frustrating bottlenecks. Read how a targeted approach to ADMET is cutting through the noise.
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
A study from Weill Cornell Medicine shows that pre-treating pancreatic islet cells with a small molecule cocktail significantly improves survival after transplantation in type 1 diabetes models. The approach could help make donor cells go further and transplants more efficient.
Shift Bioscience has published a new study introducing enhanced metrics and baselines for evaluating virtual cell models - boosting gene target discovery and accelerating its rejuvenation therapeutics pipeline.
Want to understand the real impact of AI in 3D sample analysis? This episode cuts straight to how machine learning is accelerating research and overcoming current limitations.
As ethical pressures and new regulations shake up preclinical research, the industry faces a turning point: can we finally move beyond non-human primates? Dr Mariana Argenziano, Associate Director Manufacturing Technologies at Ncardia, discusses the innovations reshaping drug development and what’s coming next.
